Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: March 30, 2023

Patent: 9,506,069

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions

Summary for Patent: 9,506,069
Title:Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization
Abstract: Methods of inhibiting lymphangiogenesis and/or angiogenesis in a subject are provided. In one aspect, for example, a method of inhibiting angiogenesis in a subject can include binding an antisense morpholino to an mRNA splicing site of VEGFR1 selected from exon13_intron13 junction, intron13_exon14 junction, or a combination thereof. In another aspect, the morpholino includes a member selected from VEGFR1_MOe13, VEGFR1_MOi13, or a combination thereof.
Inventor(s): Ambati; Balamurali K. (Sandy, UT), Uehara; Hironori (Salt Lake City, UT)
Assignee: University of Utah Research Foundation (Salt Lake City, UT)
Application Number:14/394,726
Patent Claims:see list of patent claims

Details for Patent 9,506,069

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Sign Up 2032-04-19
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign Up 2032-04-19
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Sign Up 2032-04-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.